AGM
ESPR

Alpine Global Management’s Esperion Therapeutics ESPR Stock Holding History

Alpine Global Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,731
Closed -$17.5K – 253
2025
Q2 		$17.5K Buy
+17,731
New +$17.8K ﹤0.01% 146
2024
Q3 		– Sell
-183,922
Closed -$408K – 251
2024
Q2 		$408K Buy
+183,922
New +$433K 0.07% 202
2022
Q4 		– Sell
-10,150
Closed -$68K – 505
2022
Q3 		$68K Hold
10,150
– – 0.02% 132
2022
Q2 		$65K Hold
10,150
– – 0.02% 160
2022
Q1 		$47K Sell
10,150
-8,932
-47% -$38.3K 0.01% 315
2021
Q4 		$95K Buy
+19,082
New +$153K 0.01% 659

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Alpine Global Management's ESPR Position: Q3 2025 in Review

Alpine Global Management sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 17,731 shares — an estimated $17.5K sold.

Alpine Global Management first reported a position in ESPR in Q4 2021 and held it in 6 quarters. The position peaked at $408K in Q2 2024. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Alpine Global Management reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alpine Global Management sold 17,731 Esperion Therapeutics shares in Q3 2025, an estimated $17.5K.
  • Alpine Global Management first reported a position in Esperion Therapeutics in Q4 2021 and held it in 6 quarters.
  • Alpine Global Management's Esperion Therapeutics position peaked at $408K in Q2 2024.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Alpine Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.